Taiwan News12h
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more frequently in patients treated with Iqirvo than placebo in the double-blind period ...
It’s the illness that has no cure. But this doctor believes he’s found the answer to chronic fatigue syndrome
Chronic fatigue and long Covid remain poorly understood, but Dr Perrin’s unusual techniques are having surprisingly positive ...